Home/Filings/4/0001266375-07-000052
4//SEC Filing

PROGENICS PHARMACEUTICALS INC 4

Accession 0001266375-07-000052

CIK 0000835887operating

Filed

Jul 4, 8:00 PM ET

Accepted

Jul 5, 5:25 PM ET

Size

15.9 KB

Accession

0001266375-07-000052

Insider Transaction Report

Form 4
Period: 2007-07-02
Kremer Alton B
VP, Clinical Research
Transactions
  • Award

    Common Stock

    2007-07-02+13,33329,349 total
  • Tax Payment

    Common Stock

    2007-07-02$22.01/sh775$17,05829,426 total
  • Exercise/Conversion

    Common Stock

    2007-07-02$18.71/sh+852$15,94130,201 total
  • Exercise/Conversion

    ESPP (right to buy)

    2007-07-028520 total
    Exercise: $18.71From: 2007-07-02Exp: 2007-07-03Common Stock (852 underlying)
  • Award

    ESPP (right to buy)

    2007-07-02+753753 total
    Exercise: $21.57From: 2008-01-02Exp: 2008-01-02Common Stock (753 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2007-07-02+10,00010,000 total
    Exercise: $22.01From: 2008-07-02Exp: 2017-07-02Common Stock (10,000 underlying)
Footnotes (7)
  • [F1]Restricted Stock shall be released in four equal installments, commencing one year from the transaction date.
  • [F2]Includes shares of common stock acquired from the non-reportable exercise under a Qualified Employee Stock Purchase Plan.
  • [F3]Acquired upon the complete exercise of a grant under the Non-Qualified Employee Stock Purchase Plan, which grant was previously reported at the start of a six month option term, to acquire common stock up to an option amount which is 25% of the optionee's quarterly salary less $6,250, at a purchase price equal to the lower of 100% of the market value on the date of grant or 85% of the market value on the date of exercise.
  • [F4]The option was granted on the first day of the option term and previously reported as a right to purchase shares of the Company's common stock at an exercise price equal to the market value on the date of grant. In accordance with the Non-Qualified Employee Stock Purchase Plan, the option is ultimately exercisable for an exercise price which is the lower of 100% of the market value on the grant date or 85% of the market value on the day prior to the exercise date. The number of shares exercised is based on the option amount divided by the lower of 100% of the market value on the grant date or 85% of the market value on the day prior to the exercise date.
  • [F5]Granted under the Company's Non-Qualified Employeee Stock Purchase Plan.
  • [F6]The option will be exercisable for that number of shares equal to the option amount (25% of the optionee's quarterly salary less $6,250) divided by the lesser of the market value of the common stock on the grant date or 85% of the market value on the day prior to the exercise date.
  • [F7]The stock options become exercisable in four equal installments, commencing one year from the grant date.

Issuer

PROGENICS PHARMACEUTICALS INC

CIK 0000835887

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000835887

Filing Metadata

Form type
4
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 5:25 PM ET
Size
15.9 KB